Tags: EU | France | Sanofi | Hemophilia

France's Sanofi Buys US Hemophilia Specialist Bioverativ

Monday, 22 January 2018 05:02 AM

PARIS (AP) — France-based drugmaker Sanofi is buying U.S. hemophilia specialist Bioverativ for $11.6 billion in a deal that Sanofi says will boost its profile for fighting rare diseases.

The deal announced Monday is the latest such move in a pharmaceutical industry that's seeing increasing interest in rare diseases.

Sanofi said in a statement that the boards of both companies approved the purchase, and that Sanofi will pay $105 per share in cash for all outstanding shares of Bioverativ. The Waltham, Massachusetts-based company focuses on blood disorders.

Bioverativ said it hopes its Eloctate and Alprolix hemophilia medications can reach a broader market thanks to Sanofi's global infrastructure.

Sanofi's strategy in the coming years includes expanding its rare disease portfolio, and hemophilia treatment is considered a growing market.

© Copyright 2019 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

   
1Like our page
2Share
Europe
France-based drugmaker Sanofi is buying U.S. hemophilia specialist Bioverativ for $11.6 billion in a deal that Sanofi says will boost its profile for fighting rare diseases.The deal announced Monday is the latest such move in a pharmaceutical industry that's seeing...
EU,France,Sanofi,Hemophilia
126
2018-02-22
Monday, 22 January 2018 05:02 AM
Newsmax Media, Inc.
 
 

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved